{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:07:34Z","timestamp":1732032454490},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11864-004-0012-8","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:39:28Z","timestamp":1183019968000},"page":"203-214","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapy for mycosis fungoides"],"prefix":"10.1007","volume":"5","author":[{"given":"Jeanette","family":"Lundin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/00000478-199512000-00009","volume":"19","author":"BR Smoller","year":"1995","unstructured":"Smoller BR, Bishop K, Glusac E, et al.: Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 1995, 19:1423\u20131430.","journal-title":"Am J Surg Pathol"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1523-1747.1999.00581.x","volume":"112","author":"CP Tensen","year":"1999","unstructured":"Tensen CP, Flier J, Van Der Raaij-Helmer EM, et al.: Human IP-9: a keratinocyte-derived high affinity CXCchemokine ligand for the IP-10\/Mig receptor (CXCR3). J Invest Dermatol 1999, 112:716\u2013722.","journal-title":"J Invest Dermatol"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1067\/mjd.2003.132","volume":"48","author":"T Kakinuma","year":"2003","unstructured":"Kakinuma T, Sugaya M, Nakamura K, et al.: Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003, 48:23\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0889-8588(18)30054-6","volume":"9","author":"A Rook","year":"1995","unstructured":"Rook A, Heald P: The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:997\u20131010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"12_CR5","volume-title":"Cancer: Principles and Practice of Oncology","author":"V DeVita","year":"2001","unstructured":"DeVita V, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001."},{"key":"12_CR6","first-page":"725","volume":"63","author":"PA Bunn","year":"1979","unstructured":"Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979, 63:725\u2013728.","journal-title":"Cancer Treat Rep"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1001\/archderm.136.4.504","volume":"136","author":"R van Doorn","year":"2000","unstructured":"van Doorn R, Van Haselen CW, van Voorst Vader PC, et al.: Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000, 136:504\u2013510. A multivariate analysis on prognostic factors in MF and survival rates in different stages of MF.","journal-title":"Arch Dermatol"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-4362.2003.01644.x","volume":"42","author":"HS Zackheim","year":"2003","unstructured":"Zackheim HS: Treatment of mycosis fungoides\/Sezary syndrome: the University of California, San Francisco (UCSF) approach. Int J Dermatol 2003, 42:53\u201356.","journal-title":"Int J Dermatol"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/archderm.135.11.1349","volume":"135","author":"E Esteve","year":"1999","unstructured":"Esteve E, Bagot M, Joly P, et al.: A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol 1999, 135:1349\u20131353.","journal-title":"Arch Dermatol"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1046\/j.1365-2133.2002.04802.x","volume":"147","author":"P Foulc","year":"2002","unstructured":"Foulc P, Evrard V, Dalac S, et al.: Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. Br J Dermatol 2002, 147:926\u2013930.","journal-title":"Br J Dermatol"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1001\/archderm.138.3.398","volume":"138","author":"HL Liu","year":"2002","unstructured":"Liu HL, Kim YH: Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 2002, 138:398\u2013399.","journal-title":"Arch Dermatol"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","volume":"49","author":"P Heald","year":"2003","unstructured":"Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003, 49:801\u2013815. A large phase III trial on topical bexarotene therapy in MF.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","volume":"33","author":"JJ Herrmann","year":"1995","unstructured":"Herrmann JJ, Roenigk HH Jr, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995, 33:234\u2013242.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM198702053160603","volume":"316","author":"R Edelson","year":"1987","unstructured":"Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987, 316:297\u2013303.","journal-title":"N Engl J Med"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1046\/j.1365-2133.1999.02889.x","volume":"140","author":"TM Fritz","year":"1999","unstructured":"Fritz TM, Kleinhans M, Nestle FO, et al.: Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sezary syndrome. Br J Dermatol 1999, 140:1144\u20131147.","journal-title":"Br J Dermatol"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","volume":"42","author":"B Micaily","year":"1998","unstructured":"Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 1998, 42:361\u2013364.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12_CR17","first-page":"691","volume":"63","author":"RT Hoppe","year":"1979","unstructured":"Hoppe RT, Cox RS, Fuks Z, et al.: Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979, 63:691\u2013700.","journal-title":"Cancer Treat Rep"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","volume":"32","author":"LD Wilson","year":"1995","unstructured":"Wilson LD, Licata AL, Braverman IM, et al.: Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995, 32:987\u2013995.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1067\/mjd.2000.105510","volume":"43","author":"LD Wilson","year":"2000","unstructured":"Wilson LD, Jones GW, Kim D, et al.: Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000, 43:54\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1067\/mjd.2002.123482","volume":"47","author":"GW Jones","year":"2002","unstructured":"Jones GW, Kacinski BM, Wilson LD, et al.: Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002, 47:364\u2013370. A consensus report on electron radiation in MF.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","volume":"9","author":"EA Olsen","year":"1995","unstructured":"Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1089\u20131107.","journal-title":"Hematol Oncol Clin North Am"},{"key":"12_CR22","first-page":"3578","volume":"92","author":"R Stadler","year":"1998","unstructured":"Stadler R, Otte HG, Luger T, et al.: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92:3578\u20133581. An important randomized trial involving IFN and PUVA in combination that allows the use of a lower dosage of both therapies, reducing the adverse events associated with each and increasing the response rate.","journal-title":"Blood"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0190-9622(84)80323-0","volume":"10","author":"RK Winkelmann","year":"1984","unstructured":"Winkelmann RK, Diaz-Perez JL, Buechner SA: The treatment of Sezary syndrome. J Am Acad Dermatol 1984, 10:1000\u20131004.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","volume":"34","author":"HS Zackheim","year":"1996","unstructured":"Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996, 34:626\u2013631.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","volume":"86","author":"G Akpek","year":"1999","unstructured":"Akpek G, Koh HK, Bogen S, et al.: Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999, 86:1368\u20131376.","journal-title":"Cancer"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1085-5629(00)80012-7","volume":"19","author":"JM Muche","year":"2000","unstructured":"Muche JM, Gellrich S, Sterry W: Treatment of cutaneous T-cell lymphomas. Semin Cutan Med Surg 2000, 19:142\u2013148.","journal-title":"Semin Cutan Med Surg"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0190-9622(00)90007-0","volume":"42","author":"U Wollina","year":"2000","unstructured":"Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000, 42:40\u201346.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/cncr.11593","volume":"98","author":"U Wollina","year":"2003","unstructured":"Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003, 98:993\u20131001. An important study on pegylated liposomal doxorubicin, which is a new drug for MF.","journal-title":"Cancer"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1023\/A:1008377724139","volume":"10","author":"AD Ho","year":"1999","unstructured":"Ho AD, Suciu S, Stryckmans P, et al.: Pentostatin in T-cell malignancies: a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999, 10:1493\u20131498.","journal-title":"Ann Oncol"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","volume":"17","author":"R Kurzrock","year":"1999","unstructured":"Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of Tcell lymphomas with cutaneous manifestations. J Clin Oncol 1999, 17:3117\u20133121. In this trial, escalating doses of pentostatin were used in patients with relapsed CTCL, with an OR rate of 71%.","journal-title":"J Clin Oncol"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","volume":"144","author":"JJ Scarisbrick","year":"2001","unstructured":"Scarisbrick JJ, Child FJ, Clift A, et al.: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001, 144:1010\u20131015.","journal-title":"Br J Dermatol"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","volume":"18","author":"PL Zinzani","year":"2000","unstructured":"Zinzani PL, Baliva G, Magagnoli M, et al.: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000, 18:2603\u20132606. A major trial regarding gemcitabine, which has promising activity and is well tolerated in CTCL.","journal-title":"J Clin Oncol"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","volume":"113","author":"S Sallah","year":"2001","unstructured":"Sallah S, Wan JY, Nguyen NP: Treatment of refractory Tcell malignancies using gemcitabine. Br J Haematol 2001, 113:185\u2013187.","journal-title":"Br J Haematol"},{"key":"12_CR34","first-page":"1234","volume":"8","author":"C Zhang","year":"2002","unstructured":"Zhang C, Hazarika P, Ni X, et al.: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002, 8:1234\u20131240.","journal-title":"Clin Cancer Res"},{"key":"12_CR35","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M, Martin AG, Kim Y, et al.: Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous Tcell lymphoma. Arch Dermatol 2001, 137:581\u2013593. An important trial regarding bexarotene in early-stage CTCL.","journal-title":"Arch Dermatol"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\/III trial results. J Clin Oncol 2001, 19:2456\u20132471. A large phase II\/III trial regarding bexarotene in advancedstage CTCL.","journal-title":"J Clin Oncol"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1067\/mjd.2002.124607","volume":"47","author":"R Talpur","year":"2002","unstructured":"Talpur R, Ward S, Apisarnthanarax N, et al.: Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002, 47:672\u2013684.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, et al.: Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood 2003, 101:4267\u20134272. This study verifies that alemtuzumab is highly active in CTCL.","journal-title":"Blood"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","volume":"71","author":"GA Kennedy","year":"2003","unstructured":"Kennedy GA, Seymour JF, Wolf M, et al.: Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003, 71:250\u2013256.","journal-title":"Eur J Haematol"},{"key":"12_CR40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","volume":"87","author":"S Knox","year":"1996","unstructured":"Knox S, Hoppe RT, Maloney D, et al.: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996, 87:893\u2013899.","journal-title":"Blood"},{"key":"12_CR41","first-page":"645a","volume":"102","author":"E Obitz","year":"2003","unstructured":"Obitz E, Kim H, Iversen L, et al.: HuMaX-CD4, A fully human monoclonal antibody: early results of an ongoing phase II trial in cutaneous T-cell lymphoma (CTCL) [abstract]. Blood 2003, 102:645a This paper involves a potential emerging drug in CTCL.","journal-title":"Blood"},{"key":"12_CR42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"E Olsen","year":"2001","unstructured":"Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001, 19:376\u2013388.","journal-title":"J Clin Oncol"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","volume":"1","author":"FM Foss","year":"2001","unstructured":"Foss FM, Bacha P, Osann KE, et al.: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001, 1:298\u2013302. Steroids improved response and reduced toxicity in patients with MF who were treated with denileukin diftitox.","journal-title":"Clin Lymphoma"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"731a","DOI":"10.1182\/blood-2002-09-2831","volume":"102","author":"M Donato","year":"2003","unstructured":"Donato M, Kurzrock R, Champlin R, et al.: Complete remission at late-stage mycosis fungoides\/Sezary syndrome following allogeneic transplantation. Blood 2003, 102:731a.","journal-title":"Blood"},{"key":"12_CR45","first-page":"476a","volume":"102","author":"A Molina","year":"2003","unstructured":"Molina A, Zain J, Arber D, et al.: Is allogeneic hematopoietic stem cell transplantation (AHSCT) potentially curative in a group of refractory cutaneous T-cell lymphomas (CTCLs)? Durable clinical, cytogenetic and molecular remissions after AHSCT for refractory Sezary syndrome and mycosis fungoides. Blood 2003, 102:476a.","journal-title":"Blood"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","volume":"82","author":"EH Kaplan","year":"1990","unstructured":"Kaplan EH, Rosen ST, Norris DB, et al.: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990, 82:208\u2013212.","journal-title":"J Natl Cancer Inst"},{"key":"12_CR47","first-page":"179a","volume":"102","author":"M Duvic","year":"2003","unstructured":"Duvic M, Talpur R, Chiao N, Chiao J: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral Tcell lymphoma (PTCL). Blood 2003, 102:179a. This paper involves a potential future agent in CTCL.","journal-title":"Blood"},{"key":"12_CR48","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","volume":"94","author":"AH Rook","year":"1999","unstructured":"Rook AH, Wood GS, Yoo EK, et al.: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902\u2013908.","journal-title":"Blood"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","volume":"941","author":"AH Rook","year":"2001","unstructured":"Rook AH, Zaki MH, Wysocka M, et al.: The role for interleukin-12 therapy of cutaneous T-cell lymphoma. Ann N Y Acad Sci 2001, 941:177\u2013184.","journal-title":"Ann N Y Acad Sci"},{"key":"12_CR50","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","volume":"102","author":"T Maier","year":"2003","unstructured":"Maier T, Tun-Kyi A, Tassis A, et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003, 102:2338\u20132344. This paper describes an entirely new therapeutic principle in CTCL.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0012-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-004-0012-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0012-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0012-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:34:08Z","timestamp":1659090848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-004-0012-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11864-004-0012-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}